October is PMR Month

Save

PMR has come a long way from being an occasional referral and often test question, to now being a hot area of drug development and investigation. Led by numerous investigators and educators worldwide, there are new insights into the diagnosis, management and outcomes of PMR patients, with greater clarity on how and where it differs from giant cell arteritis.

RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)

Save

This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?

Rheumatology Advocates Push for Patient Access to Care

Save

Physician members of the American College of Rheumatology (ACR), care team members of the Association of Rheumatology Professionals (ARP), and patients living with rheumatic diseases convened on Capitol Hill this week for the annual Advocates for Arthritis conference and to support legislative so

Uncertainty on Pre-Clinical RA – Rheumatologist Survey Results

Save

In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice. 

Microvascular CV Disease with Severe Psoriasis

Save

While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis. 

Advice on Multi-Drug Failures in RA

Save

What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics?  In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.  

RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)

Save

Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions. 

Cognitive-behavioral Therapy Lessens Fibromyalgia Pain

Save

In a recent randomized clinical trial of patients with fibromyalgia, cognitive-behavioral therapy (CBT)—which uses structured techniques to alter distorted thoughts and negative moods—was superior to a matched education treatment in reducing the interfering effects of pain and other aspects of fi

What Changed FDA's Mind About Ilaris for Gout?

Save

The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis -- leaving outsiders to guess at what changed in the dozen years since the company's first attempt to gain app

Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring

Save

We use biologic agents on a daily basis in the treatment of rheumatoid arthritis. Despite having an expanding array of options, our profession is keen on gaining a deeper understanding of why certain drugs fail and being able to predict the most appropriate next steps in treatment. 

TNR: Decisions in Methotrexate

Save

This Tuesday Night Rheumatology panel discussion on "Methotrexate Decisions" features Drs. Michael Weinblatt, Grace Wright, Richard Conway and Joel Kremer.

RA Associated Cancer Risk

Save

A large cohort analysis of insured rheumatoid arthritis (RA) patients reveals that RA patients have a 1.69 to 2.08 fold higher risk of developing cancer, especially lymphoma or lung cancer, within 1 year of RA diagnosis.